Researchers from the University of Oxford and their partners have reported that the malaria vaccine, R21/Matrix-M, has demonstrated high-level efficacy of 77%.
India broke records on Thursday (23 April) as more than 310,000 new COVID cases were documented in one day - is the Indian 'double mutation', B1617, as infectious as the UK mutation?
Raymond Pompon, Director of F5 Labs, looks at the cybersecurity threats to the COVID-19 vaccine amid the rise in cyber attacks since the onset of the pandemic.
In February, 16% of the world's population pre-ordered 70% of available COVID vaccines - now, researchers at Colombia University reveal that some poorer countries won't be able to vaccinate their population until 2023.
Pfizer CEO Albert Bourla suggested that fully vaccinated people would need their third vaccine dose, maybe 12 months after they got their second - the EU is currently in talks to secure a further 1.8 billion doses.
According to a Kaiser Permanente study, the rate of recommended vaccine doses administered to children has dramatically decreased since the outbreak of COVID-19.
Yesterday (14 April) EU President Ursula von der Leyen announced that the Commission would create a third contract with Pfizer, for 1.8 billion doses between 2021 to 2023.
Researchers in the UK started a clinical trial on mixing vaccines in February - today (14 April) a new study will look into mixing Moderna and Novavax doses.
US authorities paused the use of the Johnson & Johnson single dose vaccine as they look into six cases of blood clots that developed in women aged between 18 and 48.
